Enter Note Done

Session


Deepak Bhatt, Brigham and Women's Hosp, Boston, MA; Michael Szarek, SUNY Downstate, Brooklyn, NY; Philippe Steg, Hop Bichat, Paris, France; Christopher Cannon, Brigham and Women's Hosp, Boston, MA; Lawrence Leiter, Univ of Toronto, Toronto, ON, Canada; Darren McGuire, Univ Texas Southwestern Medical Ctr, Dallas, TX; Julia Lewis, Vanderbilt Univ, Nashville, TN; Matthew Riddle, Univ of Oregon, Portland, OR; Adriaan Voors, Univ Medical Ctr Groningen, Groningen, Netherlands; Marco Metra, Univ and Civil hospital of Brescia, Brescia, Italy; Lars Lund, Karolinska Instt, Stockholm, Sweden; Michel Komajda, Groupe Hospier Pitié, Paris, France; Jeffrey Testani, Yale, Guilford, CT; Christopher Wilcox, Georgetown Univ, Washington, DC; Piotr Ponikowski, Wroclaw Medical Univ, Wroclaw, Poland; Renato Lopes, Duke Univ, Durham, NC; Subodh Verma, St Michael's Hosp, Toronto, MA, Canada; Pablo Lapuerta, Lexicon Pharmaceuticals, Inc., The Woodlands, TX; Bertram Pitt, Univ of Michigan, Ann Arbor, MI; on Behalf of the SOLOIST-WHF Investigators
Disclosure Block: D.Bhatt: Research Grant; Significant; Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laborato. M.Metra: Honoraria; Modest; Amgen, Abbott Vascular, Vifor pharma, WindTree Therapeutics, Astra-Zeneca, Actelion, LivaNova, Speaker/Speaker's Bureau; Modest; Abbott Vascular, Edwards therapeutics. L.Lund: Honoraria; Modest; Novartis, Merck, Sanofi, AstraZeneca, ViforPharma, Bayer, Pharmocosmos, Research Grant; Modest; Novartis, Boehringer Ingelheim, Boston Scientific, Speaker/Speaker's Bureau; Modest; Abbott, Speaker/Speaker's Bureau; Significant; Medscape. M.Komajda: n/a. J.Testani: Honoraria; Modest; bayer, BMS, Boehiringer, Megentamed, Novartis, Windtree therapeutics, Honoraria; Significant; Cardionomic, Sequana, Reprieve medical, FIRE1, Gore, AZ, Research Grant; Significant; 3ivelabs, BMS, Boehiringer, Otsuka, Sequana, Sanofi, Sanofi, Abbott. C.Wilcox: None. P.Ponikowski: Honoraria; Significant; Vifor Pharma, Other; Significant; Vifor Pharma, Speaker/Speaker's Bureau; Significant; Vifor Pharma. R.Lopes: Other; Modest; Bayer, Boehringer Ingleheim, Daiichi Sankyo, Glaxo Smith Kline, Medtronic, Merck, Portola, Sanofi, Other; Significant; Bristol-Myers Squibb, Pfizer, Other Research Support; Significant; Bristol-Myers Squibb, Glaxo Smith Kline, Medtronic, Pfizer, Sanofi. S.Verma: Honoraria; Modest; Amgen, Janssen, Boehringer-Ingelheim/Lilly, Merck, Bayer, Novonordisk, EOCI, HLS Therapeutics, Novartis, Sanofi, Sun Pharma, Toronto Knowledge Translation Working Group, Honoraria; Significant; AstraZeneca, Research Grant; Significant; Amgen, Boehringer-Ingelheim/Lilly, Bristol-Myers Squibb, HLS Therapeutics. P.Lapuerta: n/a. B.Pitt: Honoraria; Modest; Astra Zeneca, Honoraria; Significant; Sanofi, Bayer, vifor, Stock Shareholder; Significant; KBP pharmaceuticals, scpharmaceuticals, sarfez, SQinovations , G3 pharmaceuticals, Cereno scienmtific. M.Szarek: Other Research Support; Modest; CiVi, Esperion, Other Research Support; Significant; Regeneron Pharmaceuticals, Sanofi. On behalf of the soloist-whf investigators: n/a. P.Steg: Honoraria; Significant; Amarin, Amgen, AstraZeneca, Bayer/Janssen, Boehringer-Ingelheim, Bristol-Myers-Squibb, Idorsia, Lilly, Merck, Novartis, Novo-Nordisk, Pfizer, Regeneron, Sanofi, Servier,
, Research Grant; Significant; Bayer, Merck, Sanofi, Amarin, Servier. C.Cannon: Honoraria; Modest; Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BI, BMS, Corvidia, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer Rhoshan, Honoraria; Significant; Sanofi, Research Grant; Significant; Amgen, Boehringer-Ingelheim (BI), Bristol-Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck, Pfizer. L.Leiter: Other; Modest; Astra Zeneca, Amgen, Kowa, Merck, The Medicines Company, Sanofi/Regeneron, Boehringer Ingelheim, Eli Lilly, Janssen, HLS, Bayer, Novartis, Other Research Support; Modest; Sanofi/Regeneron, Esperion, Eli Lilly, GSK, Research Grant; Modest;
Communities
Cross Specialty
Session Types
Late-Breaking Science
Featured Sessions
Yes
Science Types
Basic
Clinical
Population